Multicenter Assessment of the Safety and Efficacy of the Minnow Medical GRST™ Peripheral Catheter System

Phase 2

Terminated

• Conditions: Peripheral Vascular Disease

• Registration Number: NCT00881257
• Lead Sponsor: Vessix Vascular, Inc

Brief Summary

The objective of this clinical investigation is to evaluate the safety and efficacy of the Minnow Medical GRST™ Peripheral Catheter System in the treatment of de novo lesions in the superficial femoral artery (SFA) or the popliteal artery.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-08
• Study First Submitted: 2009-04-13
• Study First Submitted QC: 2009-04-14
• Study First Posted: 2009-04-15
• Primary Completion: 2009-11
• Study Completion: 2010-05
• Status Verified: 2013-06
• Last Update Submitted: 2013-06-19
• Last Update Posted: 2013-06-20

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 78

Inclusion Criteria

1. Patient is ≥18 of age.
2. Patient is Rutherford category 2-4.
3. De novo single lesion with a diameter stenosis (%DS) of ≥50%
4. Target lesion is a de novo occlusion that can be successfully pre-dilated resulting in a lesion of <99%.
5. Target lesion stenosis has a length of ≤100 mm based on visual assessment.
6. Target vessel reference diameter is ≥3.0 mm and ≤7.0 mm based on visual assessment.
7. Angiographic evidence of distal runoff defined as minimum one patent tibial artery with a straight flow to the foot.
8. Patient is willing and able to provide written informed consent prior to any study specific procedure.
9. Patient is willing and able to comply with specified follow-up evaluations at the specified times.

Exclusion Criteria

1. Prior PTA in the intended target lesion including 10 mm proximal or distal from the intended treatment area.
2. Evidence of thrombus in the target vessel.
3. Prior ipsilateral or contralateral lower limb arterial bypass.
4. Treatment of ipsilateral lesions during the index procedure or planned treatment after the index procedure.
5. Target lesion is severely calcified.
6. Any known allergies and / or intolerances to the following: ASA, Clopidogrel, Heparin, contrast agents (that cannot be adequately pre-medicated).
7. Any planned surgery within 30 days of the study procedure.
8. Renal failure (serum creatinine > 2.0 mg/dL).
9. Female with childbearing potential without a negative pregnancy test.
10. Patient has had an organ transplant.
11. Patient is currently participating in an investigational drug or device study which has not reached the primary endpoint yet or which clinically interferes with the endpoints of this study.
12. In the investigator's opinion, the patient has a severe co-morbid condition(s) that could limit the ability to participate in the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Major Adverse Clinical Events Rate	Up to 30 days

Secondary Outcome Measures

Name	Time	Method
Binary Restenosis	30 days, 3 months, 6 months and 12 months
Target Lesion Revascularization	30 days, 3 months, 6 months and 12 months
Amputation Rate	30 days, 3 months, 6 months, and 12 months
Technical Success	Treatment
Serious Adverse Events rate, including Major Adverse Clinical Events	30 days, 3 months, 6 months, and 12 months

Trial Locations

Locations (2)

Herz-Zentrum Bad Krozingen; 🇩🇪 Bad Krozingen, Germany

Hamburg University Cardiovascular Center; 🇩🇪 Hamburg, Germany